PharmGKB summary: Tamoxifen pathway, pharmacokinetics

Pharmacogenetics and Genomics

Volumn 23, Issue 11, 2013, Pages 643-647

  Klein, Daniel J ^a   Thorn, Caroline F ^a   Desta, Zeruesenay ^b   Flockhart, David A ^b   Altman, Russ B ^a   Klein, Teri E ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Pathway; Pharmacogenomics; Tamoxifen

Indexed keywords

AFIMOXIFENE; DRUG METABOLITE; ENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN; TAMOXIFEN N OXIDE; UNCLASSIFIED DRUG;

ABCC2 GENE; ARTICLE; CYP2C19 GENE; CYP2D6 GENE; DRUG MECHANISM; DRUG METABOLISM; GENE; GENETIC VARIABILITY; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SULT1A1 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; UGT2B15 GENE;

ANTINEOPLASTIC AGENTS, HORMONAL; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; PHARMACOGENETICS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84886582469     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283656bc1     Document Type: Article

References (53)

1. Boocock DJ, Maggs JL, Brown K, White IN, Park BK. Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alphahydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis 2000; 21: 1851-1858.
2. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-1075.
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
4. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318.
5. Moyer AM, Suman VJ, Weinshilboum RM, Avula R, Black JL, Safgren SL, et al. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics 2011; 12: 1535-1543.
6. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193.
7. Goetz MP, Loprinzi CL. A hot flash on tamoxifen metabolism. J Natl Cancer Inst 2003; 95: 1734-1735.
8. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008; 165: 1251-1255.
9. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758-1764.
10. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618.
11. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-120.
12. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113-121.
13. Jin Y, Desta Z, Stearns V,Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
14. Takimoto CH. Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments? Nat Clin Pract Oncol 2007; 4: 152-153.
15. Jordan VC, Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 1975; 11: 205-206.
16. Lippman ME, Bolan G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 1975; 256: 592-593.
17. Allen KE, Clark ER, Jordan VC. Evidence for the metabolic activation of nonsteroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 1980; 71: 83-91.
18. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977; 75: 305-316.
19. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003; 2: 205-213.
20. Lu WJ, Desta Z, Flockhart DA. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 2012; 131: 473-481.
21. Lu WJ, Xu C, Pei Z, Mayhoub AS, Cushman M, Flockhart DA. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 2012; 133: 99-109.
22. Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet 2012; 27: 122-131.
23. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708-717.
24. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-Ndesmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 1988; 48: 2304-2308.
25. Borges S, Desta Z, Li L, Skaar TC,Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74.
26. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 2009; 69: 1722-1727.
27. Parte P, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 2005; 33: 1446-1452.
28. Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, et al. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat 2012; 134: 693-700.
29. Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther 2011; 337: 710-717.
30. Teft WA, Mansell SE, Kim RB. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos 2011; 39: 558-562.
31. Falany JL, Pilloff DE, Leyh TS, Falany CN. Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos 2006; 34: 361-368.
32. Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 2010; 10: 313.
33. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010; 28: 1287-1293.
34. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002; 94: 1635-1640.
35. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 2007; 35: 2006-2014.
36. Hertz DL, McLeod HL, Irvin WJ Jr. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 2012; 17: 620-630.
37. Brauch H, Schroth W, Goetz MP, Murdter TE, Winter S, Ingle JN, et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013; 31: 176-180.
38. Owen RP, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2D6. Pharmacogenet Genomics 2009; 19: 559-562.
39. Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24: 3708-3709, author reply 3709.
40. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007; 25: 3837-3845.
41. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M,Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436.
42. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91: 249-258.
43. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B,Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9:R7.
44. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7:R284-R290.
45. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 452-460.
46. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104: 441-451.
47. Goldberg P. Experts claim errors in breast cancer study, demand retraction of practice-changing paper. Cancer Lett 2012; 38: 1-11.
48. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 2012; 104: 1266-1268, 1264; author reply.
49. Stanton V Jr. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 2012; 104: 1265-1266, author reply 1266-1268.
50. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, et al. Heterogeneity of study populations impacts the effect of CYP2D6 genotype in the adjuvant tamoxifen treatment of breast cancer. Clin Pharmacol Ther 2013; in press.
51. Skierka JM,Walker DL, Peterson SE, O'Kane DJ, Black JL III. CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene. Pharmacogenomics 2012; 13: 951-954.
52. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, et al. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 2009; 115: 391-396.
53. Kiyotani K, Mushiroda T, Tsunoda T, Morizono T, Hosono N, Kubo M, et al. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet 2012; 21: 1665-1672.